Eqqualberry NAD+ Peptide Boosting Trial Kit (3 sachet kits)
₨ 950
In stock
Eqqualberry NAD Peptide Boosting Trial Kit
Upgrade your skincare routine with the Eqqualberry NAD+ Peptide Boosting Trial Kit, a high-performance anti-aging set designed to energize, firm, and restore your skin.
Description
This advanced routine combines the power of NAD+ and peptides to support skin renewal, improve elasticity, and enhance overall radiance.
Formulated to target early signs of aging and fatigue, this trial kit works to strengthen the skin barrier, boost hydration, and promote a smoother, more lifted appearance. The lightweight yet nourishing textures absorb effortlessly, delivering visible results without heaviness.
Key Benefits:
- Boosts skin energy and supports renewal
- Improves firmness and elasticity
- Helps reduce fine lines and early signs of aging
- Deeply hydrates and strengthens the skin barrier
- Enhances overall glow and skin vitality
Key Ingredients:
- NAD+: Helps support cellular energy and skin regeneration
- Peptides: Improve elasticity and promote firmer, smoother skin
What’s Inside:
A complete mini routine featuring NAD+ and peptide-infused essentials to cleanse, treat, and hydrate for visibly revitalized skin.
How to Use:
Use the products in sequence as part of your daily skincare routine. Follow with sunscreen during the day.
Who It’s For:
Suitable for all skin types, especially those experiencing dullness, loss of firmness, or early aging concerns.
Recharge your skin, boost resilience, and reveal a firmer, more radiant complexion.
Related products
COSRX Advanced Snail 96 Mucin Power Essence
COSRX Advanced Snail 96 Mucin Power Essence 03.08.2026 expiry date of 30mL size The COSRX Advanced Snail 96 Mucin Power
3CE Plumping Lips shade PINK
heimish Artless Glow Base SPF50+ PA+++ 40mL (renewal)
Beauty of Joseon Green Plum Refreshing Cleanser 100mL
Green Plum Refreshing Cleanser is a slightly acidic cleanser that helps to cleanse the face without damaging the natural skin

Reviews
Clear filtersThere are no reviews yet.